S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

$38.65
+1.20 (+3.20%)
(As of 03/27/2024 ET)
Today's Range
$36.71
$39.04
50-Day Range
$18.56
$41.60
52-Week Range
$6.71
$42.88
Volume
787,120 shs
Average Volume
1.29 million shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.86

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.5% Upside
$38.86 Price Target
Short Interest
Bearish
8.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Alpine Immune Sciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

725th out of 939 stocks

Pharmaceutical Preparations Industry

334th out of 433 stocks

ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

ALPN Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Evaluating Alpine Immune Sciences: Insights From 6 Financial Analysts
Q4 2023 Alpine Immune Sciences Inc Earnings Call
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.86
High Stock Price Target
$50.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+0.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-54.49%

Debt

Sales & Book Value

Annual Sales
$58.88 million
Book Value
$5.64 per share

Miscellaneous

Free Float
37,820,000
Market Cap
$2.53 billion
Optionable
Optionable
Beta
1.13
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price target for 2024?

7 brokerages have issued 1 year target prices for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $50.00. On average, they anticipate the company's stock price to reach $38.86 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 at the beginning of the year. Since then, ALPN shares have increased by 102.8% and is now trading at $38.65.
View the best growth stocks for 2024 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,610,000 shares, an increase of 26.6% from the February 29th total of 4,430,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 5.1 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to analysts' expectations of $22.30 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%.

What ETF holds Alpine Immune Sciences' stock?

AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio.

What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Decheng Capital LLC (12.19%), Great Point Partners LLC (6.37%), Frazier Life Sciences Management L.P. (5.39%), Vanguard Group Inc. (3.85%), Vanguard Group Inc. (3.85%) and Price T Rowe Associates Inc. MD (2.90%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALPN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners